NASDAQ:AKER

Akers Biosciences (AKER) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.74
$2.85
50-Day Range
$2.47
$4.59
52-Week Range
$1.65
$6.97
Volume
20,266 shs
Average Volume
769,876 shs
Market Capitalization
$46.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKER stock logo

About Akers Biosciences Stock (NASDAQ:AKER)

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

AKER Stock News Headlines

World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Cam Akers Becomes A Free Agent
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Jennifer C. Akers
See More Headlines
Receive AKER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2018
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:AKER
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-3,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.58 million
Book Value
$5.38 per share

Miscellaneous

Free Float
N/A
Market Cap
$46.79 million
Optionable
Not Optionable
Beta
0.30
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Christopher C. Schreiber (Age 56)
    CEO, Pres & Director
    Comp: $507.62k
  • Mr. Ian Rhodes (Age 48)
    Interim Chief Financial Officer
  • Mr. Gary M. Rauch (Age 65)
    VP of Fin. & Treasurer

AKER Stock Analysis - Frequently Asked Questions

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) released its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) EPS for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter.

What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO?

3 employees have rated Akers Biosciences Chief Executive Officer Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioPharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

This page (NASDAQ:AKER) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners